MetaVia reports Q2 2026 results, all patients reach top DA-1726 doses
MetaVia said patients in its Phase 1 Part 3 study of DA-1726 have reached the highest planned dose levels, with 16-week topline data expected in Q4 2026.
SEC filing
Latest
1 story
Sign in